Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance

Endocrinology

Volumn 151, Issue 10, 2010, Pages 4678-4687

  Ayala, Julio E ^a,c   Bracy, Deanna P ^a   James, Freyja D ^a   Burmeister, Melissa A ^c   Wasserman, David H ^a   Drucker, Daniel J ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN KINASE B; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; FAT INTAKE; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ATHEROGENIC DIET; C57BL MOUSE; DRUG EFFECTS; FAT INTAKE; FEMALE; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; PHYSIOLOGY; SEXUAL DEVELOPMENT; SKELETAL MUSCLE;

ADIPOSITY; ANIMALS; DIET, ATHEROGENIC; DIETARY FATS; FEMALE; GLUCOSE; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SKELETAL; RECEPTORS, GLUCAGON; SEX CHARACTERISTICS;

EID: 77957259261     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0289     Document Type: Article

References (53)

1. Thorens B 1992 Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89:8641-8645
2. Campos RV, Lee YC, Drucker DJ 1994 Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134:2156-2164
3. Bullock BP, Heller RS, Habener JF 1996 Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:2968-2978 (Pubitemid 26192194)
4. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y 1999 Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 96:14843-14847
5. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S 1989 Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38:902-905
6. Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ 1995 Glucagon-like peptide I reduces post-prandial glycemic excursions in IDDM. Diabetes 44:626-630
7. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH 1997 Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981-E988
8. de Heer J, Rasmussen C, Coy DH, Holst JJ 2008 Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51:2263-2270
9. Ayala JE, Bracy DP, Hansotia T, Flock G, Seino Y, Wasserman DH, Drucker DJ 2008 Insulin action in the double incretin receptor knockout mouse. Diabetes 57:288-297
10. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN 1988 Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37:1163-1167
11. Collins S, Martin TL, Surwit RS, Robidoux J 2004 Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiol Behav 81:243-248
12. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH 2007 Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 56:1025-1033
13. Gault VA, Irwin N, Green BD, McCluskey JT, Greer B, Bailey CJ, Harriott P, O'Harte FP, Flatt PR 2005 Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54:2436-2446
14. Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR 2007 Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 50:1752-1762
15. McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR 2007 GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 293:E1746-E1755
16. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y 2002 Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8:738-742
17. Yamada C, Yamada Y, Tsukiyama K, Yamada K, Yamane S, Harada N, Miyawaki K, Seino Y, Inagaki N 2007 Genetic inactivation of GIP signaling reverses aging-associated insulin resistance through body composition changes. Biochem Biophys Res Commun 364:175-180
18. Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, Drucker DJ 2009 The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 150:1155-1164
19. Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, Cabou C, Colom A, Uldry M, Rastrelli S, Sabatier E, Godet N, Waget A, Pénicaud L, Valet P, Burcelin R 2008 Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 149:4768-4777
20. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH 2006 Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55:390-397
21. Berglund ED, Li CY, Poffenberger G, Ayala JE, Fueger PT, Willis SE, Jewell MM, Powers AC, Wasserman DH 2008 Glucose metabolism in vivo in four commonly used inbred mouse strains. Diabetes 57:1790-1799
22. Chan TM, Exton JH 1976 A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal Biochem 71:96-105
23. Steele R, Wall JS, De Bodo RC, Altszuler N 1956 Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187:15-24
24. DeBodo RC, Steele R, Altszuler N, Dunn A, Bishop JS 1963 On the hormonal regulation of carbohydrate metabolism: studies with C14 glucose. Recent Prog Horm Res 19:445-488
25. Kraegen EW, James DE, Jenkins AB, Chisholm DJ 1985 Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am J Physiol 248:E353-E362
26. Fueger PT, Bracy DP, Malabanan CM, Pencek RR, Wasserman DH 2004 Distributed control of glucose uptake by working muscles of conscious mice: roles of transport and phosphorylation. Am J Physiol Endocrinol Metab 286:E77-E84
27. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S 1992 Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322
28. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW 1994 Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266
29. D'Alessio DA, Prigeon RL, Ensinck JW 1995 Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes 44:1433-1437
30. Shalev A, Ninnis R, Keller U 1998 Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men. Horm Res 49:221-225
31. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Finegood DT, Elahi D 2001 Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 24:1951-1956 (Pubitemid 33716507)
32. Egan JM, Meneilly GS, Habener JF, Elahi D 2002 Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 87:3768-3773 (Pubitemid 34879525)
33. Prigeon RL, Quddusi S, Paty B, D'Alessio DA 2003 Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 285:E701-E707 (Pubitemid 37176420)
34. Azuma K, Rádikova Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, He Y, Ligueros- Saylan M, Serra D, Foley JE, Kelley DE 2008 Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 93:459-464
35. Orskov L, Holst JJ, Møller J, Orskov C, Møller N, Alberti KG, Schmitz O 1996 GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39:1227-1232 (Pubitemid 26319947)
36. Toft-Nielson M, Madsbad S, Holst JJ 1996 The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45:552-556 (Pubitemid 26140536)
37. Ahrén B, Larsson H, Holst JJ 1997 Effects of glucagon-like peptide- 1 on islet function and insulin sensitivity in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478 (Pubitemid 27068614)
38. Ryan AS, Egan JM, Habener JF, Elahi D 1998 Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin- mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83:2399-2404 (Pubitemid 28503037)
39. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA 2000 Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 49:611-617 (Pubitemid 30183750)
40. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA 2002 Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 45:1410-1415
41. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, Drucker DJ 2007 Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 117:143-152 (Pubitemid 46048461)
42. Cabou C, Campistron G, Marsollier N, Leloup C, Cruciani- Guglielmacci C, Pénicaud L, Drucker DJ, Magnan C, Burcelin R 2008 Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 57:2577-2587
43. Baron AD 1994 Hemodynamic actions of insulin. Am J Physiol 267:E187-E202
44. Baron AD, Tarshoby M, Hook G, Lazaridis EN, Cronin J, Johnson A, Steinberg HO 2000 Interaction between insulin sensitivity and muscle perfusion on glucose uptake in human skeletal muscle: evidence for capillary recruitment. Diabetes 49:768-774 (Pubitemid 30339992)
45. Clark MG, Wallis MG, Barrett EJ, Vincent MA, Richards SM, Clerk LH, Rattigan S 2003 Blood flow and muscle metabolism: a focus on insulin action. Am J Physiol Endocrinol Metab 284:E241-E258
46. Fujii N, Jessen N, Goodyear LJ 2006 AMP-activated protein kinase and the regulation of glucose transport. Am J Physiol Endocrinol Metab 291:E867-E877
47. Zheng D, Ionut V, Mooradian V, Stefanovski D, Bergman RN 2009 Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver. Diabetes 58:352-359
48. Brown MS, Goldstein JL 2008 Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7:95-96
49. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ 1996 Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2:1254-1258
50. Scrocchi LA, Marshall BA, Cook SM, Brubaker PL, Drucker DJ 1998 Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 47:632-639
51. Baggio LL, Huang Q, Brown TJ, Drucker DJ 2004 A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53:2492-2500
52. Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Grémeaux T, Drucker DJ, Kahn CR, Girard J, Tanti JF, Delzenne NM, Postic C, Burcelin R 2005 Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115:3554-3563 (Pubitemid 43121843)
53. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ 2008 Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 57:2046-2054